ARA1 Antibody

What is ARA1 Antibody and what specific protein does it recognize?

ARA1 Antibody recognizes SART1 (Squamous Cell Carcinoma Antigen Recognized by T-cells 1), a protein also known by multiple alternative names including Hom s 1, HOMS1, SART1259, SNU66 Homolog, and hSnu66. The antibody targets this approximately 110 kDa protein which functions as a component of the U4/U6.U5 tri-snRNP complex involved in pre-mRNA splicing . In experimental applications, it's important to note that ARA1/SART1 can refer to different proteins depending on the experimental context - in human cells it refers to the splicing-associated protein, while in Saccharomyces cerevisiae it can refer to D-arabinose dehydrogenase, and in Arabidopsis thaliana it may refer to arabinose kinase . Researchers should carefully verify the specific target when selecting an ARA1 antibody for their experiments.

What are the primary applications of ARA1 Antibody in research settings?

ARA1/SART1 antibodies support multiple experimental applications, with Western Blot (WB) being the most consistently supported across different antibody sources. Based on available research tools, these antibodies can be effectively utilized in:

• Western Blot (WB): For protein detection and quantification

• Immunofluorescence (IF): For subcellular localization studies

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative analysis

• Immunohistochemistry (IHC): For tissue section analysis

• Immunoprecipitation (IP): For protein-protein interaction studies

• Immunocytochemistry (ICC): For cellular localization

• Flow Cytometry (FC/FACS): For cell sorting and quantitative analysis

Each application requires specific optimization, and researchers should select antibodies validated for their particular application of interest. For example, some rabbit anti-SART1 antibodies are specifically validated for immunoprecipitation while others are optimized for Western blot applications .

How do different host species affect ARA1 Antibody performance in experimental systems?

The host species in which an ARA1 antibody is produced significantly impacts its experimental performance characteristics. Common host species include:

Multiple purification methods are employed, including:

• Affinity purification

• Protein A affinity chromatography

• Antigen affinity chromatography

• Immunoaffinity chromatography

The selection of host species should be guided by the experimental design, particularly when conducting co-localization studies that require antibodies from different host species to avoid cross-reactivity issues.

How can researchers optimize experimental design to ensure ARA1 Antibody specificity?

Ensuring ARA1 antibody specificity requires careful experimental design, particularly since SART1/ARA1 can refer to different proteins across species. Researchers should implement:

• Multiple validation strategies: Employ orthogonal approaches (e.g., siRNA knockdown followed by Western blot; recombinant protein controls) to verify target specificity.

• Cross-reactivity assessment: Test the antibody against related proteins, particularly other components of the splicing machinery that might share structural similarities.

• Specificity selection: Consider using computationally designed antibodies with enhanced specificity profiles. Recent research demonstrates that "biophysically interpretable models trained on experimentally selected antibodies can associate distinct binding modes with specific ligands, enabling the prediction and generation of highly specific variants" . This approach has shown success in designing antibodies that can discriminate between structurally and chemically similar ligands.

• Multiple epitope targeting: When studying complex proteins like SART1, use antibodies targeting different epitopes to verify results and reduce epitope-specific artifacts. This is particularly important when the target protein may exist in multiple conformations or interaction states within the spliceosome complex .

• Controls for post-translational modifications: Consider how phosphorylation or other modifications might affect epitope recognition.

A combination of these approaches significantly increases confidence in experimental results when working with ARA1 antibodies.

What computational approaches can enhance ARA1 Antibody specificity for closely related epitopes?

Recent advances in computational biology offer promising approaches for enhancing antibody specificity, which can be applied to ARA1/SART1 antibodies:

• Biophysics-informed modeling: This approach "associates each potential ligand with a distinct binding mode, enabling the prediction and generation of specific variants beyond those observed in experiments" . For ARA1 antibody research, this can help distinguish between closely related epitopes.

• Integration of phage display with computational analysis: By combining "phage display experiments, high-throughput sequencing, and machine learning techniques," researchers can develop models that "not only predict physical features but also design new proteins with specific properties" . This methodology is particularly valuable for designing antibodies capable of discriminating between structurally and chemically similar ligands.

• Multi-target selection experiments: Using data from "antibody selection against diverse combinations of closely related ligands," researchers can train models to predict outcomes for new ligand combinations . This approach has successfully generated antibody variants "not present in the initial library that are specific to a given combination of ligands" .

• Specificity profile customization: Computational design can create antibodies with either "specific high affinity for a particular target ligand, or with cross-specificity for multiple target ligands" . This flexibility is valuable for researchers requiring different binding profiles depending on their experimental goals.

These computational methodologies help overcome limitations of traditional selection-based approaches, which are "limited in terms of library size and control over specificity profiles" .

How can researchers validate contradictory results obtained with different ARA1 Antibody clones?

When facing contradictory results with different ARA1 antibody clones, researchers should implement a systematic validation approach:

• Epitope mapping: Determine if different antibodies recognize distinct epitopes on the ARA1/SART1 protein, which might be differentially accessible in various experimental conditions or cellular contexts.

• Binding mode analysis: Apply biophysical models to identify if "different binding modes [are] associated with a particular ligand against which the antibodies are either selected or not" . This can reveal if competing antibodies are recognizing the same epitope through different binding mechanisms.

• Cross-validation with non-antibody methods: Employ orthogonal techniques such as mass spectrometry, CRISPR-based gene editing, or RNA interference to verify protein identity, localization, or function.

• Comprehensive controls table: Document a systematic matrix of experimental controls:

• Differential post-translational modification detection: Assess whether different antibodies might be sensitive to phosphorylation, glycosylation, or other modifications of ARA1/SART1 .

This systematic approach helps resolve contradictions and may reveal biologically relevant insights about protein isoforms or modification states.

What are the best practices for using ARA1 Antibody in Western Blot analyses?

For optimal Western blot results with ARA1/SART1 antibodies, follow these methodological recommendations:

• Sample preparation optimization:

  • Include protease inhibitors to prevent degradation of the ~110 kDa SART1 protein

  • For nuclear proteins like SART1, use nuclear extraction protocols (rather than whole cell lysates) to enrich target concentration

  • Denature samples thoroughly at 95°C for 5 minutes in loading buffer containing SDS and DTT to ensure complete protein denaturation

• Gel electrophoresis parameters:

  • Use 8-10% SDS-PAGE gels for optimal resolution of the 110 kDa SART1 protein

  • Run at 100V through stacking gel, then 150V through resolving gel

  • Include molecular weight markers spanning 50-150 kDa range

• Transfer and blocking conditions:

  • Transfer at 100V for 90 minutes using PVDF membrane for higher protein retention

  • Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

  • For phospho-specific detection, use 5% BSA instead of milk

• Antibody selection and dilution:

  • Rabbit anti-SART1 antibodies typically perform well in Western blot applications at 1:1000 dilution

  • Incubate primary antibody overnight at 4°C for optimal signal-to-noise ratio

  • Use secondary antibodies at 1:5000 dilution, incubating for 1 hour at room temperature

• Detection optimization:

  • For weak signals, consider enhanced chemiluminescence Plus (ECL+) reagents

  • Expose for different durations (30 seconds to 5 minutes) to capture optimal signal

• Controls and validation:

  • Include positive control (cell line known to express SART1)

  • Include negative control (SART1 knockdown or knockout cell line)

  • For new antibodies, confirm specificity with peptide competition assay

Following these methodological details will enhance detection specificity and sensitivity when working with ARA1/SART1 antibodies in Western blot applications.

How should researchers optimize immunoprecipitation protocols when using ARA1 Antibody?

Optimizing immunoprecipitation (IP) with ARA1/SART1 antibodies requires attention to several critical parameters:

• Antibody selection:

  • Choose antibodies specifically validated for IP applications, such as antigen affinity-purified rabbit anti-SART1 antibodies

  • Polyclonal antibodies often perform better than monoclonals for IP of native proteins

• Lysis buffer optimization:

  • For nuclear proteins like SART1, use nuclear extraction buffers containing 0.1-0.5% NP-40 or Triton X-100

  • Include protease inhibitors, phosphatase inhibitors, and RNase inhibitors (particularly important when studying splicing factors)

  • Buffer composition example:

    • 50 mM Tris-HCl (pH 7.4)

    • 150 mM NaCl

    • 0.3% NP-40

    • 1 mM EDTA

    • 1× protease inhibitor cocktail

    • 1× phosphatase inhibitor cocktail

    • 40 U/mL RNase inhibitor

• Pre-clearing strategy:

  • Pre-clear lysates with protein A/G beads (30 minutes at 4°C) to reduce non-specific binding

  • Pre-clear with species-matched IgG for additional specificity

• Antibody binding conditions:

  • Use 2-5 μg antibody per 500 μg protein lysate

  • Incubate overnight at 4°C with gentle rotation

  • Add pre-equilibrated protein A/G beads for 1-2 hours

• Washing protocol optimization:

  • Perform 4-5 washes with progressively stringent buffers:

    • First wash: lysis buffer

    • Middle washes: lysis buffer with increased salt (250-300 mM NaCl)

    • Final wash: low-salt buffer (50 mM Tris-HCl)

• Elution strategy:

  • For protein analysis: elute with SDS sample buffer at 95°C for 5 minutes

  • For maintaining protein-protein interactions: use gentler elution with peptide competition

• Validation approaches:

  • Always run IgG control IP in parallel

  • Confirm successful IP by Western blot for SART1

  • For novel interactions, validate with reverse IP using antibodies against the interacting partner

This optimized protocol addresses the specific challenges of immunoprecipitating nuclear splicing factors like SART1/ARA1 while maintaining native protein interactions.

What are the key considerations for immunofluorescence studies using ARA1 Antibody?

When conducting immunofluorescence (IF) studies with ARA1/SART1 antibodies, researchers should address these methodological considerations:

• Fixation and permeabilization optimization:

  • For nuclear proteins like SART1, use 4% paraformaldehyde (PFA) fixation (10 minutes at room temperature)

  • Permeabilize with 0.2-0.5% Triton X-100 (10 minutes) to ensure antibody access to nuclear proteins

  • Avoid methanol fixation which can destroy some epitopes

• Blocking parameters:

  • Block with 5% normal serum from the species of secondary antibody

  • Include 0.1% BSA and 0.1% Triton X-100 in blocking buffer

  • Block for 30-60 minutes at room temperature

• Antibody selection and validation:

  • Choose antibodies specifically validated for IF applications

  • Validate antibody specificity using siRNA knockdown controls

  • Typical working dilution range: 1:100 to 1:500 for primary antibodies

• Nuclear counterstaining strategy:

  • Use DAPI (1 μg/mL) for nuclear visualization

  • Consider using antibodies against other splicing factors for co-localization studies

• Imaging parameters:

  • Capture Z-stacks to fully visualize nuclear distribution

  • Use confocal microscopy for detailed nuclear speckle pattern analysis

  • Image multiple fields to account for cell-to-cell variability

• Expected localization pattern:

  • SART1/ARA1 typically shows nuclear localization with enrichment in nuclear speckles

  • Visualization table:

• Controls:

  • Primary antibody omission control

  • Peptide competition control

  • siRNA knockdown visualization

  • Differential controls when using multiple antibodies from the same host species

Following these detailed methodological considerations will enhance the specificity and reproducibility of immunofluorescence studies using ARA1/SART1 antibodies.

How can researchers address non-specific binding issues when using ARA1 Antibody?

Non-specific binding is a common challenge with antibodies including those targeting ARA1/SART1. Implement these methodological solutions:

• Antibody validation hierarchy:

  • Confirm antibody specificity through knockout/knockdown controls

  • Verify single band at expected molecular weight (~110 kDa for SART1)

  • Test multiple antibodies targeting different epitopes

• Buffer optimization strategies:

  • Increase blocking agent concentration (5-10% serum or BSA)

  • Add 0.1-0.5% non-ionic detergent (Triton X-100, Tween-20)

  • Include carrier proteins (0.1-0.5% BSA) in antibody dilution buffers

  • Consider adding 5% non-fat dry milk to reduce hydrophobic interactions

• Antibody dilution optimization:

  • Test serial dilutions to find optimal concentration

  • Extend primary antibody incubation time (overnight at 4°C) with more dilute antibody

• Cross-adsorption techniques:

  • Pre-adsorb antibody with acetone powder from non-target species

  • For tissues, block endogenous biotin/avidin when using biotinylated detection

  • Pre-incubate with recombinant protein fragments to confirm specificity

• Differential non-specific binding troubleshooting guide:

• Advanced computational approaches:

  • Apply biophysics-informed modeling to predict potential cross-reactive epitopes

  • Use antibodies designed through computational approaches showing enhanced specificity

Implementing these methodological solutions systematically will help researchers troubleshoot and overcome non-specific binding issues when working with ARA1/SART1 antibodies.

What quantitative methods should researchers use to analyze ARA1/SART1 expression data?

Robust quantitative analysis of ARA1/SART1 expression requires appropriate methodological approaches:

• Western blot quantification protocol:

  • Use loading controls appropriate for nuclear proteins (Lamin B1, Histone H3)

  • Apply densitometry with linear dynamic range verification

  • Normalize SART1 signal to loading control using software like ImageJ

  • Perform triplicate biological replicates with statistical analysis (ANOVA with post-hoc tests)

• Immunofluorescence quantification strategies:

  • Measure nuclear intensity using nucleus-specific masks

  • Quantify nuclear speckle number, size, and intensity

  • Use automated image analysis with CellProfiler or similar software

  • Analyze >100 cells per condition to account for cell-to-cell variability

• RT-qPCR validation approach:

  • Design primers spanning exon-exon junctions specific to SART1

  • Normalize to multiple reference genes (GAPDH, ACTB, TBP)

  • Calculate relative expression using the 2^(-ΔΔCt) method

  • Correlate mRNA and protein expression changes

• Statistical analysis framework:

  • Apply appropriate statistical tests based on data distribution

  • Use multiple comparison corrections (Bonferroni, FDR) when testing multiple conditions

  • Report effect sizes with confidence intervals, not just p-values

  • Create comprehensive visualization of statistical outcomes:

• Integration with transcriptomics data:

  • Correlate SART1 protein levels with splicing changes in target transcripts

  • Analyze differential exon usage using RNA-seq

  • Apply computational models to relate SART1 expression to splicing outcomes

These quantitative methodological approaches provide a comprehensive framework for analyzing ARA1/SART1 expression data with statistical rigor and biological relevance.

How can researchers distinguish between closely related splicing factors when studying ARA1/SART1?

Distinguishing SART1/ARA1 from other splicing factors requires precise methodological approaches:

• Epitope-based differentiation strategy:

  • Select antibodies targeting unique epitopes absent in related splicing factors

  • Validate antibody specificity with recombinant protein arrays containing multiple splicing factors

  • Employ custom peptide competition assays with peptides from SART1 and related proteins

• Multi-modal protein identification approach:

  • Combine immunological detection with mass spectrometry validation

  • Use targeted proteomics (SRM/MRM) to quantify specific SART1 peptides

  • Implement isotope-labeled protein standards for absolute quantification

• Co-localization analysis methodology:

  • Perform high-resolution co-localization studies with other known splicing factors

  • Calculate Pearson's correlation coefficients for spatial overlap

  • Analyze distance relationships between different splicing factors using:

• Functional discrimination approaches:

  • Implement selective knockdown/knockout of SART1 vs. other factors

  • Analyze differential effects on specific splice junctions

  • Use RNA-protein crosslinking methods (CLIP) to identify unique binding sites

  • Apply computational models to distinguish binding modes

• Biophysical property analysis:

  • Examine differential extraction properties with increasing salt concentrations

  • Analyze protein complex assembly/disassembly kinetics

  • Study differential phosphorylation patterns affecting function

Employing these methodological approaches enables researchers to precisely distinguish SART1/ARA1 from other closely related splicing factors, ensuring experimental specificity when studying this important component of the U4/U6.U5 tri-snRNP complex.